Prestige Consumer Healthcare Inc. (PBH) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025 (Q2 of Fiscal Year 2026). Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter (OTC) health and personal care products in North America and international markets. The company operates two reportable segments: North American OTC Healthcare and International OTC Healthcare.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $274.1 million | $283.8 million | $523.6 million | $550.9 million |
| Gross Profit | $151.6 million | $157.4 million | $291.9 million | $303.4 million |
| Gross Margin % | 55.3% | 55.5% | 55.7% | 55.1% |
| Operating Income | $79.7 million | $84.3 million | $151.4 million | $156.4 million |
| Net Income | $42.2 million | $54.4 million | $89.7 million | $103.4 million |
| Diluted EPS | $0.86 | $1.09 | $1.81 | $2.06 |
| Operating Cash Flow (YTD) | $136.5 million (vs. $124.6 million YTD 2024) | |||
| Long-Term Debt | $1.0 billion (Fixed rate notes; $0 revolver balance) | |||
| Cash & Equivalents | $119.1 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3.4% in Q2 and 5.0% YTD compared to the prior year. The decline was driven primarily by the North American segment (-3.8% Q2, -6.1% YTD), specifically due to supply constraints in the Eye & Ear Care category (Clear Eyes) and lower sales in Women's Health and Cough & Cold categories.
- Profitability Pressure: Net income decreased 22.4% in Q2 and 13.3% YTD. While gross margins remained relatively stable or improved slightly due to product mix, the revenue decline and a significant increase in the effective tax rate impacted bottom-line results.
- Tax Rate Increase: The effective tax rate rose to 38.9% in Q2 (from 24.1% prior year) and 31.5% YTD (from 20.5% prior year). Management attributed this increase primarily to establishing a taxable presence in a new state.
- Share Repurchases: The company accelerated buybacks, repurchasing approximately $109.8 million of common stock YTD 2025 compared to $37.8 million YTD 2024. As of September 30, 2025, $138.7 million remained under the $300 million authorization.
Outlook, Risks, and Management Commentary
- Supply Chain Constraints: Management highlighted ongoing shortages of ingredients and products, particularly in eye care, due to third-party manufacturer difficulties. These shortages negatively impacted sales and are expected to continue affecting results.
- Economic Environment: The company faces volatility from inflation, rising input costs, labor shortages, and geopolitical events. Consumer purchasing patterns are shifting toward online channels.
- Legislative Impact: The "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025. Management does not expect it to materially impact the estimated annual effective tax rate.
- Liquidity: The company maintains $119.1 million in cash and a $190 million undrawn revolving credit facility. Management believes cash flow from operations and existing facilities are adequate for the next 12 months.
- Concentration Risk: Walmart and Amazon accounted for approximately 20% and 13% of gross revenues, respectively, in Q2 2025. One third-party supplier accounted for approximately 22% of gross revenues YTD 2025.
Investor Verification Checklist
- Supply Chain Resolution: Verify the timeline for resolving Eye & Ear Care (Clear Eyes) shortages and the impact on future revenue recovery.
- Tax Rate Sustainability: Confirm whether the elevated effective tax rate (31.5% YTD) is a permanent structural change due to the new state presence or a one-time discrete event.
- Supplier Concentration: Assess the risk associated with the single supplier representing 22% of gross revenues and the lack of long-term contracts with certain key manufacturers.
- Share Repurchase Pace: Monitor the remaining $138.7 million buyback authorization and its impact on future cash flow and liquidity.
- International Margins: Review the International segment's gross margin compression (down to 53.7% YTD) caused by inflation and product mix.